Stockscreener 앱 받기
6.96
4.53%
-0.33
시간 외 거래:
7.06
0.10
+1.44%
전일 마감가:
$7.29
열려 있는:
$7.4
하루 거래량:
4.95M
Relative Volume:
1.86
시가총액:
$1.53B
수익:
$52.04M
순이익/손실:
$-290.50M
주가수익비율:
-4.7812
EPS:
-1.4557
순현금흐름:
$-240.94M
1주 성능:
-27.88%
1개월 성능:
-36.15%
6개월 성능:
-18.02%
1년 성능:
-37.07%
1일 변동 폭
$6.935
$7.425
1주일 범위
$6.935
$9.38
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
6.96 | 2.12B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences - Yahoo Finance
Operating income of Ocular Therapeutix Inc – HAN:0OT - TradingView
RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential - Investing.com Nigeria
ETFs Investing in Ocular Therapeutix Inc Stocks - TradingView
OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights - Stocktwits
Precision Trading with Ocular Therapeutix Inc. (OCUL) Risk Zones - Stock Traders Daily
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History - ca.finance.yahoo.com
Ocular Therapeutix (OCUL) Dropped, So What Is Behind The Latest Attention? - Simply Wall Street
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst? - AlphaStreet
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success - TradingView
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a 171% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment - HCPLive
Ocular Therapeutix, Inc.Common Stock (NQ: OCUL - The Chronicle-Journal
New Ocular Therapeutix Target Price Amid Support - TheStreet Pro
Nine new hires receive stock awards at Ocular Therapeutix - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI - Glance by Eyes On Eyecare
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com
HC Wainwright & Co. reiterates Buy rating on Ocular Therapeutix, $25 price target - TradingView
Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI By Investing.com - Investing.com Nigeria
Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4 - marketscreener.com
Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI - Investing.com
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD - Stock Titan
Ocular Therapeutix (OCUL) Up 5.8% to $11.26, Testing Key Resistance at $11.82Insider Buying Alerts - careplusvn.com
OCUL News | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs - Yahoo Finance
Ocular Therapeutix (OCUL) COO sells shares to cover taxes - Stock Titan
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ocular Therapeutix (NASDAQ: OCUL) holder to sell 1,099 shares - Stock Titan
This Insider Has Just Sold Shares In Ocular Therapeutix - webull.com
Ocular Therapeutix Inc. (OCUL) Peer Comparison – Compare with Others - Value Research
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Dugel sells $233,159 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Heier sells $35,530 in stock - Investing.com
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares By Investing.com - Investing.com Nigeria
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares - Investing.com
Ocular Therapeutix CDO Peter Kaiser sells $32,686 of OCUL shares - Investing.com
Ocular Therapeutix (NASDAQ: OCUL) exec share sale covers RSU tax withholding - Stock Titan
Ocular Therapeutix CEO Dugel sells $233,159 in shares - Investing.com
Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale - stocktitan.net
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update - Yahoo Finance
META_TITLE_QUOTE - Yahoo Finance
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn
Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn
Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
0.82%
자본화:
|
볼륨(24시간):